Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

The clinical application of Lamivgudine in interdiction of Maternal-to-Child transmission for the HBsAg,HBeAg-positive pregnant women

GUO Yong-ze,LI Shu-xia,GE Su-lan,et al.Department of Digestion,Affiliated Hospital of Hebei Project University,Hebei,Handan056029,China  
Objective To observe the effect of Lamivudine on interdiction of Maternal-to-Child transmission for the HBsAg,HBeAg-positive pregnant women.MethodsOne hundred and ten cases of HBsAg,HBeAg double-positive pregnant women and infants were randomly divided into lamivudine group(70 cases) and control group(40 cases).In lamivudine group,patients started to take lamivudine 100mg /day from the 28th week of pregnancy and ended until delivery.In control group,patients didn't take lamivudine.The infants from both groups vaccinated HBIG and hepatitis B.At birth and the 7th month,collect vein blood of infants from two groups,and serum HBsAg,anti-HBs and HBV-DNA were tested.ResultsAt the birth,peripheral blood HBsAg,HBV-DNA positive rate of the study group was significantly lower than control one;the serum anti-HBs-positive rate of study group was greatly higher than the control one;the positive peripheral anti-HBs transfer rate of study group at the 7th months was significantly higher than the control one.ConclusionThe integrated vaccination of neonatal hepatitis B immunoglobulin(HBIG) and hepatitis B(HBvac) could interdict the maternal-to-child transmission of HBV by lamivudine for HBsAg,HBeAg-positive pregnant women.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved